Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

US11046743B2 · kind B2 · utility

Assignee

• ANTAROS MEDICAL AB · SE

Inventors

• Torsten Haack · Frankfurt am Main, DE
• Oliver Plettenburg · Kelkheim, DE
• Andreas Evers · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE
• Martin Bossart · Frankfurt am Main, DE
• Romain BERTRAND · Paris, FR

Key dates

• Filing date: Dec 12, 2016
• Grant date: Jun 29, 2021
• Expiry date: Sep 16, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.